Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics.
Karamouzis
M V
MV
Konstantinopoulos
P A
PA
Papavassiliou
A G
AG
D000818:Animals; D066246:ErbB Receptors / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000503:physiopathology*; D015398:Signal Transduction / Q000502:physiology*
D066246:ErbB Receptors